Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431770 | 0.72 | APAF1 (0.34) | APAF1TDP2NSD2HKDC1DNMT1 | |
| SCHEMBL2599344 | 0.52 | S100A4 (1.00) | S100A4APAF1TDP2DNMT1ALDH1A1 | |
| SCHEMBL7260223 | 0.51 | APAF1 (1.00) | S100A4APAF1TDP2NSD2HKDC1 | |
| SCHEMBL21584067 | 0.49 | INMT (0.39) | ALDH1A1 | |
| SCHEMBL12020975 | 0.48 | — | — | |
| SCHEMBL4067337 | 0.48 | — | — | |
| SCHEMBL1698475 | 0.46 | INMT (0.40) | ALDH1A1MAPT | |
| SCHEMBL8600693 | 0.45 | PTPN1 (0.75) | NSD2HKDC1ALDH1A1MAPT | |
| SCHEMBL11755346 | 0.45 | INMT (0.39) | ALDH1A1 | |
| SCHEMBL6752722 | 0.45 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | S100A4 3251/4885APAF1 4604/4885TDP2 2581/4885 |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | S100A4 3251/4885APAF1 4604/4885TDP2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.